Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.

Effectiveness for patients treatment with original

Time frame · 24 Months

At the different moments of analysis (6, 12 and 24 months of treatment) in each of the treatment groups will be presented. The 95% confidence interval will be calculated for the mean percent change difference between groups. Likewise, the Student's t-test will be calculated for independent samples to assess statistical significance. To determine the fracture rate of any location during the study, the percentage of patients in each of the groups will be calculated descriptively. This proportion of patients will be compared between groups using Pearson's Chi-square test or Fisher's exact test, when applicable. The baseline-final change in biochemical markers of bone remodeling (BRM) between treatment groups will also be evaluated through the Student's t-test for independent samples if they meet the normality parameters or, failing that, its corresponding non-parametric test. (Mann-Whitney U test). .

Confirm fracture rate in any localization while study is ongoing

Time frame · 30 Months

In order to determinate fracture rate from any localization, patient´s percentage from each group will be calculated in a descriptive way using: Bone fractures during treatment Falls.

Demographic and personal aspects related to the risk of osteoporosis

Time frame · 24 Months

age, sex, province of residence, year of diagnosis of OP.

Risk factor of osteoporosis

Time frame · 30 Months

As per previous patient´s medical records. Phisician will evaluated risk factor as per clinical practice. This information will be available at Clinical Records for each patients.

Previous clinical data

Time frame · 24 Months

Family history of interest as per clinical practice. This information will be available at Clinical Records for each patients.

Anthropometric clinical data

Time frame · 24 Months

weight and height will be combined to report BMI in kg/m\^2

Osteoporosis diagnosis

Time frame · 24 Months

By BMD; BMD data in CL and hip, measured value in g/cm2 and T-Score value.

TBS

Time frame · 24 Months

TBS value

FRAX

Time frame · 24 Months

FRAX value of hip and major fracture.

Bone remodelling biomarkers

Time frame · 24 Months

Combined information described by: BGP (ng/ml), CTX (ng/ml), NTX (nmol/nmol creatine), P1NP (ng/ml), 25 OH vitamin D (ng/ml), intact PTH (pg/ml), TSH uUl/ml), Testosterone (ng/ml), Estradiol (pg/ml), Calcium (mg/dl), Phosphorus (mg/dl).This information will be collected in 194 patients who were recruited in this study. This information will be collected as per protocol during 30months. Physicians will evaluated this parameters as per clinical practice.

Hepatic profile

Time frame · 24 Months

Combined information described by: SGPT (U/L), SGOT (U/L), Gamma GT (U/L), FA (U/L), BT (mg/dl). This information will be collected in 194 patients who were recruited in this study. This information will be collected as per protocol during 30months. Physicians will evaluated this parameters as per clinical practice.